Clinical Trial Update: Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory Cancer [Phase 1]

View source ↗

Summary

Phase I trial evaluating the safety, pharmacokinetics, and pharmacodynamics of GSK923295 in patients with refractory cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• GSK923295

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cancer | Phase 1 | Status: COMPLETED